The idiopathic Intracranial Hypertension Treatment Trial was the first randomized double-masked placebo controlled trial for the management of IIH. The results of the study have given us additional insight to this disease as well as enabled us to better manage patients with new treatment strategies.
Advanced in clinical and bench research in ophthalmology has produced multiple new treatment options for a variety of ocular diseases. New technology, including the fast growing field of ocular imaging, is been used to further understand eye anatomy and pathology. Progress in the field of ocular surgery has introduced new techniques and better outcomes. The clinical and research environment is complex; issues related to ethics, quality improvement and new technology affect all eye care providers. The Eye Institute has, as one of its mission, the goal of being at the forefront of research, clinical care and education. Our goal is to educate the academic and community eye care providers, residents, researchers and medical students on the best and newest clinical and surgical treatments, cutting edge research and important non-clinical topics available in the field.
- Community eye care professionals
- Full time faculty
- Fellow ophthalmologists
- Ophthalmic photographers
At the conclusion of this activity, I will be able to:
- List the diagnostic criteria for IIH
- Discuss treatment for IIH
- List high risk characteristics in IIH
Peter A. Quiros, MD
Associate Professor of Ophthalmology
University of California, Los Angeles
In accordance with the ACCME® Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.